NEWSpublisher 2007 :: AngloChinese Investments
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
from:    to: 
R & D
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Beijing Joinn Pharmaceutical Center back to previous page show list

Beijing Joinn Pharmaceutical Center

address: Address: Beijing Joinn Pharmaceutical Center, Jia NO.5,Rongjing East Street, Beijing Economic and Technological Development Area .+P.R.China
Zip Code: 100176
contact: Tel: 86-10-67869966
Fax: 86-10-67875783
Contact: Conglin Zuo
key person: Peizhong Li
Former Director of Chinese Pharmacologic Soiety, Director, Toxicology Scientific Committee of Chinese Pharmacology
Zhiwen Zhou
MD, MBA , Chairman & Managing Director
Yuxia Feng
MD, Managing Director

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO


Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
Ingredients: NO
Western Generics: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: YES
New materials Safety Assessment: YES
Pharmaceuticals: YES
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
Licensed Drugs: NO

Company Overview:
Founded in 1995, BEIJING JOINN PHARMACEUTICAL CENTER (Abbreviated as JOINN) is the first private Contract Research Organization (CRO) engaged in both pre-clinical and clinical services.
JOINN provides a series of services that include pre-clinical studies, clinical trials, and new drug registration. After more than ten years of hard work, JOINN has obtained extensive experience in pre-clinical studies and clinical studies, especially in safety evaluation of investigational new drug, such as animal toxicities.
JOINN built a state-of-art research facility in Beijing Economic and Technological Development Area in 2004. It has 2500 m2 of animal care facilities and 1500 m2 of research laboratories. A GLP certificate has been issued to our center by SFDA in April 2005. JOINN is striving to meet the international standard, and is committed to provide our clients with quality, cost-effective, professional and innovative service.
Quality Assurance  
JOINN has established a strong, dedicated Quality Assurance Department backed by professionals from different disciplines.
Quality assurance team functions in the areas of
· Implementation of Quality Systems in line with GLP & GCP
· Internal audits
· Internal Quality checks
· Participation in Proficiency testing
· Redressal of customer complaints and feedback
· Training needs of Scientific Personnel
Standard Operating Procedures (SOPs)
JOINN has developed hundreds of SOPs to meet the Quality System requirements. Each SOP deals with the rationale of the study, test system, protocol, techniques, evaluation of the findings and conclusions.
The SOPs find their application in the following:
· Administration
· Actualization of the experimentation
· Technology of the experimentation
· Use of apparatus
· Audit of QAU
· Administration of animal care facility
Peizhong Li
Former Director of Chinese Pharmacologic Soiety, Director, Toxicology Scientific Committee of Chinese Pharmacology
Zhiwen Zhou
MD, MBA , Chairman & Managing Director
Yuxia Feng
MD, Managing Director
Conglin Zuo
MD, Director
MD, vice-director Technical
Yanqing Sun
Director of the Pathology Division
Jun Li
MD, Director of the Pathology Division
Achievements in 1995-2006  
Achievements in 1995-2006 
JOINN evaluated 165 new drugs in the past decade. It included bio-pharmaceuticals, chemical drugs and Chinese medicine. The indications of these drugs are anti-tumour, anti-voris, immune-modulator, diabetes, hematological diseases and so on. The pre-clinical studies of the first marketed gene-therapeutic drug in the world were conducted at JOINN. We also have conducted more than 650 pre-clinical studies, 129 of which are chronicle toxicity studies. We have used thousands of rodents, beagle dogs, and monkeys.
JOINN started the first clinical trial of NGF in 1997. Since then we completed 36 clinical trials (phaseI-IV)
All the final reports of our studies were approved by SFDA and some were reviewed by US FDA. We have around 100 national and international clients.
Pre-clinical Studies
1. Screening  
‚óŹPreliminary evaluation of pharmacology, pharmacokinetics and toxicity for a candidate
2. Pharmacodynamics
3. Safety Pharmacology
‚óŹRespiratory system
‚óŹCirculatory system
‚óŹCentral nervous system
‚óŹOther systems
4. General Toxicity
‚óŹAcute toxicity studies
‚óŹChronicle toxicity studies
5„ÄĀSpecialty Toxicity
‚óŹImmunogenecity study
‚óŹHaemolysis test
‚óŹLocal toxicity test
‚óŹGenetic toxicity
‚óŹReproductive toxicity
‚óŹCarcinogenecity study
6„ÄĀPharmacokinetics and Toxicokinetics
Clinical Trial
‚óŹProtocol Design
‚óŹCRF Design
‚óŹInvestigators (PT) Selection
‚óŹInvestigator's Brochure Preparation
‚óŹTrial Organization and Management
‚óŹTrial Monitoring and auditing
‚óŹSerious Adverse Event (SAE) Report and Evaluation
‚óŹData Collection and Analysis
‚óŹClinical Meeting Organization and Execution„ÄÄ
Register Services
‚óŹInvestigational New Drug (IND) registration
‚óŹDiagnostic Regents and Devices Registration
‚óŹMedical Devices Registration
‚óŹHealthy food Registration

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.